INmune
Bio (NASDAQ: INMB), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune system to fight
disease, today announced that its Co-Founder and CEO RJ Tesi, M.D., will
present at the 2nd Annual Advances in Immuno-Oncology USA Congress taking place
on October 8-9 in San Diego. In addition, Dr. Tesi and Director of Neuroscience
CJ Barnum, Ph.D., will present at the World Immunotherapy Congress taking place
from October 15-17 in Basel, Switzerland. “The immuno-oncology field is rapidly
growing, and emerging new therapies are at the center of attention,” Dr. Tesi
said in the news release. “With 30% of breast cancer patients being HER2+,
trastuzumab has made significant strides in the treatment of breast cancer.
Yet, many HER2+ breast cancer patients have shown resistance to the drug. In my
presentation during the Advances in Immuno-Oncology USA Congress, I will
address one of the reasons for the resistance – specifically the presence of
the MUC4 biomarker – and how we may be able to use a soluble TNF inhibitor,
such as our drug candidate INB03, to increase the efficacy of trastuzumab in
those women who have shown resistance.”
To view the full press release, visit http://ibn.fm/8q6Ut
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded, clinical-stage
biotechnology company developing therapies targeting the innate immune system
to fight disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid-derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. For more information, visit the company’s website
at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
